Actively Recruiting
Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-09-22
135
Participants Needed
1
Research Sites
301 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The development of the retinal vascular network is completed during the third trimester of pregnancy and and the first 15 days of life of the newborn. This late maturation can be problematic in cases of preterm births and result in immature retinal vascularization, known as retinopathy of prematurity (ROP). Among the various factors influencing retinal vascular development, the tissue content of omega-3 polyunsaturated fatty acids (PUFAs) appears to be a crucial element. In a previous project, OMEGA-ROP, we showed a difference in the blood bioavailability of omega-3 PUFAs in infants born at less than 28 weeks of amenorrhea who develop ROP compared to healthy newborns with no retinopathy. This study also showed that mothers experienced variations in the blood levels of omega-3 PUFAs that were contrary to the types of variations observed in their children. This suggests a sequestration of omega-3 PUFAs in the mothers of children who will develop ROP. This new project aims to better understand the underlying molecular mechanisms by studying the expression levels of placental fatty acid receptors in relation to the development of ROP in newborns.
CONDITIONS
Official Title
Study of the Involvement of Fatty Acids in Retinopathy of Prematurity: Relationship Between Retinopathy of Prematurity and the Rate of Expression of Transplacental Fatty Acid Receptors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Mothers giving birth to premature babies less than 29 weeks of amenorrhea, after obtaining their non-opposition
- Mothers giving birth at term between 39 and 41 weeks plus 6 days, after obtaining their non-opposition
- Age 18 years or older
- Mothers not under legal protection
You will not qualify if you...
- Mothers giving birth between 29 weeks and 38 weeks plus 6 days of amenorrhea
- Mothers in critical condition
- Persons not affiliated with national health insurance
- For full-term mothers: those with past or current health conditions affecting a previous pregnancy such as vascular issues (pregnant hypertension, preeclampsia), gestational diabetes, intrauterine growth retardation, or infections during pregnancy (toxoplasmosis, cytomegalovirus, rubella, measles, chickenpox)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Dijon Bourogne
Dijon, France, 21000
Actively Recruiting
Research Team
C
Catherine CREUZOT-GARCHER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here